SRC-RAC1 signaling drives drug resistance to BRAF inhibition in de-differentiated cutaneous melanomas

Rare gain-of-function mutations in RAC1 drive drug resistance to targeted BRAF inhibition in cutaneous melanoma. Here, we show that wildtype RAC1 is a critical driver of growth and drug resistance, but only in a subset of melanomas with elevated markers of de-differentiation. Similarly, SRC inhibiti...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Eliot Y., Riordan, Jesse D., Vanneste, Marion, Henry, Michael D., Stipp, Christopher S., Dupuy, Adam J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9587254/
https://www.ncbi.nlm.nih.gov/pubmed/36271142
http://dx.doi.org/10.1038/s41698-022-00310-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9587254/
https://www.ncbi.nlm.nih.gov/pubmed/36271142
http://dx.doi.org/10.1038/s41698-022-00310-7

Ejemplares similares